Retifanlimab

Generic Name: Retifanlimab

Brand Names: Zynyz

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2079108-44-2

Unique Ingredient Identifier: 2Y3T5IF01Z

Background: Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells...

Indication: Retifanlimab is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.

Associated Conditions: Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma

Associated Therapies: -

Clinical Trials

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

Phase 2

Recruiting

Conditions: Dedifferentiated Liposarcoma

Interventions: Drug: Pemigatinib
Drug: Retifanlimab

First Posted Date: 2024-04-29

Last Posted Date: 2024-10-08

Lead Sponsor: Lund University Hospital

Target Recruit Count: 33

Registration Number: NCT06389799

Locations: 🇳🇴
Oslo University Hospital HF, Oslo, Norway
🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪
Skåne University Hospital, Lund, Sweden

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm

Interventions: Biological: Axatilimab
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Procedure: Positron Emission Tomography
Biological: Retifanlimab

First Posted Date: 2024-03-20

Last Posted Date: 2024-12-16

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 38

Registration Number: NCT06320405

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: INCB161734
Drug: Cetuximab
Drug: Retifanlimab
Drug: GEMNabP
Drug: mFOLFIRINOX

First Posted Date: 2023-12-21

Last Posted Date: 2024-12-16

Lead Sponsor: Incyte Corporation

Target Recruit Count: 466

Registration Number: NCT06179160

Locations: 🇪🇸
Fundacian Jimnez Diaz, Madrid, Spain
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
Stanford University, Palo Alto, California, United States

and more 31 locations

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Phase 2

Recruiting

Conditions: Recurrent WHO Grade 4 Glioma
Recurrent Glioblastoma

Interventions: Biological: Bevacizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Electronic Health Record Review
Radiation: Hypofractionated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Biological: Retifanlimab

First Posted Date: 2023-12-07

Last Posted Date: 2024-11-19

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 134

Registration Number: NCT06160206

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Retifanlimab
Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Drug: N-803
Drug: SX-682

First Posted Date: 2023-11-29

Last Posted Date: 2024-11-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06149481

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Phase 3

Recruiting

Conditions: Metastatic Breast Cancer
Breast Neoplasm
End Stage Cancer
Breast Cancer
Breast Cancer Metastatic

Interventions: Drug: Treatment of Physician's Choice
Biological: SV-BR-1-GM
Drug: Cyclophosphamide
Drug: Interferon infiltration of the inoculation site
Drug: Retifanlimab

First Posted Date: 2023-10-10

Last Posted Date: 2024-10-29

Lead Sponsor: BriaCell Therapeutics Corporation

Target Recruit Count: 404

Registration Number: NCT06072612

Locations: 🇺🇸
Sheboygan Cancer & Blood Specialists, Sheboygan, Wisconsin, United States
🇺🇸
Hoag Hospital Center, Irvine, California, United States
🇺🇸
Hoag Hospital Irvine, Irvine, California, United States

and more 33 locations

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Phase 2

Recruiting

Conditions: Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
Clinical Stage IV Merkel Cell Carcinoma AJCC v8
Merkel Cell Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Retifanlimab
Drug: Tuparstobart
Drug: Verzistobart

First Posted Date: 2023-09-28

Last Posted Date: 2024-03-20

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT06056895

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

Phase 2

Recruiting

Conditions: Merkel Cell Carcinoma

Interventions: Drug: Retifanlimab
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2022-10-26

Last Posted Date: 2024-05-06

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 36

Registration Number: NCT05594290

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
Grade 3b Follicular Lymphoma
High Grade B-Cell Lymphoma

Interventions: Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Biological: Retifanlimab
Biological: Rituximab and Hyaluronidase Human
Biological: Tafasitamab
Drug: Vincristine
Procedure: Bone Marrow Aspiration
Procedure: Multigated Acquisition Scan
Other: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Biospecimen Collection
Drug: Polatuzumab Vedotin

First Posted Date: 2022-07-13

Last Posted Date: 2024-11-20

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT05455697

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Trametinib
Drug: Ruxolitinib
Drug: Retifanlimab

First Posted Date: 2022-07-01

Last Posted Date: 2023-11-28

Lead Sponsor: Peter Hosein, MD

Target Recruit Count: 35

Registration Number: NCT05440942

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy